[{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"LX2006","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Adverum Biotechnologies \/ LEXEO Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Adverum Biotechnologies \/ LEXEO Therapeutics"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-L-opsin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFR A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFR A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFR A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFR A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGFR A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGFR A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGFR A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Ray Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"AAV.7m8","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adverum Biotechnologies \/ Ray Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Adverum Biotechnologies \/ Ray Therapeutics"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Adverum Biotechnologies
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
